all projects

Value added
of German
pharmaceutical exports

Client

Roche

Year

2023


The pharmaceutical industry is one of Germany’s most important export industries. In recent years, the export of pharmaceutical products has seen above-average growth compared to the other export sectors. In addition, research and development play a prominent role for pharmaceutical companies.

Our new study for Roche focuses on these two aspects. It examines the extent to which the German pharmaceutical industry is particularly value-added intensive and innovative in its exports. 

Pharmaceutical exports generate above-average value-added 

Compared to those in the other industries, German pharmaceutical exports are characterised by above-average value-added intensity and growth dynamics. This means that the export of pharmaceutical products (for example, worth one million euros) is linked to more domestic value added and jobs than the average German export of one million euros.

In an international comparison, the German pharmaceutical industry is shown to be one of the most important players on the world market and has been able to maintain its share of world exports in recent years.

Germany's share of global pharmaceutical patents is declining

In terms of research, the German pharmaceutical industry is losing ground on its international competitors:

  • In terms of research and development expenditure in relation to sales, the pharmaceutical industry is among the two most research-intensive German industrial sectors. Their absolute research expenditure has also risen at an above average rate in recent years.
  • The high global innovation dynamics in the pharmaceutical research sector is also reflected in patents: during the period under review, the number of pharmaceutical patents increased twice as much as the total number of patents worldwide.
  • However, Germany as a research location was not able to keep up with this dynamic. The German share of worldwide patents has fallen noticeably in recent years, due, in particular, to a high increase in the patent activity of the Chinese and Korean research locations.
  • On the one hand, this indicates that global pressure for innovation is likely to remain high in the coming years. On the other, this is a warning signal: in the future, a relative loss of importance in terms of innovation could also lead to a relative loss of importance on the market side – marked by shrinking world export shares. 

Our approach

For this detailed investigation of the German pharmaceutical industry in a national and international comparison, we relied on the available statistical data. This was then analysed with the help of the Prognos model landscape.

Links and downloads

To the study (PDF in German)

Further information, in German (Roche website)

Project team: Dr Georg Klose, Dr Andreas Sachs, Johann Weiss 

Latest update: 07.12.2023

Do you have questions?

Your contact at Prognos

Johann Weiß

Senior Project Manager

View profile

Mehr Studien & Projekte zu diesem Thema

More studies & projects on this topic

Mid-term evaluation of the Single Market Programme (SMP)

2025
| Project

The Single Market Programme promotes the EU internal market in order to strengthen it, standardise it and make it more competitive. Prognos was involved in the mid-term evaluation of the programme.

Design and implementation of the Resilience Expo

ongoing
| Project

Prognos is supporting the North Rhine-Westphalian Ministry of the Environment in organising, implementing and establishing the world's first trade exhibition for the climate adaptation industry.

Mid-term evaluation of the public sector loan facility

2025
| Project

The Public Sector Loan Facility is an EU financial instrument to ensure a socially just transition to climate neutrality in the regions. Prognos and t33 srl evaluated the instrument.

German industry’s resilience and sovereignty

2025
| Project

German industry is heavily dependent on raw materials and intermediate products from abroad, especially from China. Prognos analysed supply chains and developed recommendations for action.

Evaluation of the ‘Innovative University’ funding initiative

ongoing
| Project

How can innovations be implemented in practice? This is where the BMBF's ‘Innovative University’ funding initiative comes in. Prognos and Fraunhofer ISI are evaluating the programme.

Evaluation of the Federal Funding for Efficient Buildings (BEG)

ongoing
| Project

On behalf of the BMWK, we evaluate the impact of the BEG in the funding period 2021 – 2025 together with ifeu, ITG, and FIW.

Technologies to combat the shortage of skilled workers

2025
| Expertise

Specialists waste a lot of time on tiresome routine tasks. 3D planning tools or digital twins can help. Our analysis for the Fraunhofer IGD shows which professional groups benefit directly from their digital technologies.

How far are the regions on the road to a circular economy?

2025
| Project update

Prognos has developed a tool for the Circular Cities and Regions Initiative (CCRI) that supports cities and regions in monitoring their circular economy activities.

How dependent are we really on the US and China?

2025
| Expertise

Foreign trade, employment, investment and raw materials: ahead of the new US administration taking office, we analysed for the Süddeutsche Zeitung how dependent our economy is on the US and China.

Economic potential of the green tech sector in Bavaria

2024
| Project

How powerful is the green tech industry in Bavaria? What is its economic significance? We examined these questions on behalf of the vbw using our envigos model.

About us

Prognos – Providing Orientation.

Prognos is one of the oldest economic research centres in Europe. Founded at the University of Basel, Prognos experts have been conducting research for a wide range of clients from the public and private sectors since 1959 – politically independent, scientifically sound.

Learn more